| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/08/2004 | EP1453835A2 Adenosine a 2a receptor antagonists |
| 09/08/2004 | EP1453834A1 Anhydrous crystal form of valaciclovir hydrochloride |
| 09/08/2004 | EP1453832A1 Ring fused pyrazole derivatives |
| 09/08/2004 | EP1453831A1 1h-pyrrolo(3,2-b)pyridine-3-carboxylic acid amides |
| 09/08/2004 | EP1453830A1 Pyrazolo-pyridine derivatives as antiherpes agents |
| 09/08/2004 | EP1453829A1 Sulfonamido substituted imidazopyridines |
| 09/08/2004 | EP1453828A2 Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| 09/08/2004 | EP1453826A1 Amorphous form of 2-n-butyl-3-[[2-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4'] non-1-en-4-one |
| 09/08/2004 | EP1453825A1 N-ureido-piperidines as antagonists viii for ccr-3 receptor |
| 09/08/2004 | EP1453824A1 New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| 09/08/2004 | EP1453820A1 Substituted 6h-dibenzo c,h]chromenes as estrogenic agents |
| 09/08/2004 | EP1453819A2 Statin-like compounds |
| 09/08/2004 | EP1453816A2 Phenoxy amine compounds and compositions for delivering active agents |
| 09/08/2004 | EP1453815A1 Metabotropic glutamate receptor-5 modulators |
| 09/08/2004 | EP1453812A2 Cytotoxic agents |
| 09/08/2004 | EP1453811A2 Peroxisome proliferator activated receptor agonists |
| 09/08/2004 | EP1453810A1 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same |
| 09/08/2004 | EP1453806A1 Aminotetralin derivatives as muscarinic receptor antagonist |
| 09/08/2004 | EP1453805A1 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists |
| 09/08/2004 | EP1453804A2 Ccr-3 receptor antagonists vii |
| 09/08/2004 | EP1453803A2 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) |
| 09/08/2004 | EP1453801A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 09/08/2004 | EP1453800A2 Protein kinase inhibitors |
| 09/08/2004 | EP1453798A2 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| 09/08/2004 | EP1453797A1 Process for the preparation of an enantiomerically enriched thio compound |
| 09/08/2004 | EP1453796A2 Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same |
| 09/08/2004 | EP1453795A2 Esters and amides as ppar-alpha agonists |
| 09/08/2004 | EP1453793A2 New pharmaceutical compounds |
| 09/08/2004 | EP1453792A1 Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease |
| 09/08/2004 | EP1453791A1 Acetyl l-carnitine salt with a dicarboxilic organic acid and process for preparing same |
| 09/08/2004 | EP1453790A2 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof |
| 09/08/2004 | EP1453789A2 N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| 09/08/2004 | EP1453788A1 Substituted hydroxyethylamines |
| 09/08/2004 | EP1453787A1 Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor |
| 09/08/2004 | EP1453783A1 Substituted aryl-cycloalkanes, and use thereof as anticancer agents |
| 09/08/2004 | EP1453782A2 Substituted phenyl naphthalenes as estrogenic agents |
| 09/08/2004 | EP1453777A1 Functionalized higher diamondoids |
| 09/08/2004 | EP1453743A2 Pharmaceutical product with an adsorbent |
| 09/08/2004 | EP1453548A2 Compositions for and methods of treating and preventing sirs/sepsis |
| 09/08/2004 | EP1453545A1 Water-soluble polymer conjugates of retinoic acid |
| 09/08/2004 | EP1453544A2 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 09/08/2004 | EP1453531A2 Use of hmgb proteins and nucleic acids that code therefor |
| 09/08/2004 | EP1453528A2 Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 09/08/2004 | EP1453527A2 Method for obtaining oestrogen from mare urine |
| 09/08/2004 | EP1453523A1 Heparin-containing ophthalmic agent |
| 09/08/2004 | EP1453522A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist |
| 09/08/2004 | EP1453521A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 09/08/2004 | EP1453520A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances |
| 09/08/2004 | EP1453519A2 Aqueous ifosfamide composition |
| 09/08/2004 | EP1453518A1 Pharmaceutical composition for the treatment of disorders of non-human mammals |
| 09/08/2004 | EP1453517A1 Platinum derivative pharmaceutical formulations |
| 09/08/2004 | EP1453516A2 Novel tri-substituted pyrimidines, method for production and use thereof as medicament |
| 09/08/2004 | EP1453515A2 Method to treat cystic fibrosis |
| 09/08/2004 | EP1453514A1 Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma |
| 09/08/2004 | EP1453513A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| 09/08/2004 | EP1453512A1 Acetylene derivatives having mglur 5 antagonistic activity |
| 09/08/2004 | EP1453511A1 Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases |
| 09/08/2004 | EP1453510A2 Neurotransmitter balance chemotherapy |
| 09/08/2004 | EP1453508A1 Tempamine compositions and use against cellular oxidative damage |
| 09/08/2004 | EP1453507A2 Solubilized topoisomerase poison agents |
| 09/08/2004 | EP1453506A2 Topoisomerase poison agents |
| 09/08/2004 | EP1453505A2 Use of pramipexole to treat amyotrophic lateral sclerosis |
| 09/08/2004 | EP1453504A1 Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation |
| 09/08/2004 | EP1453503A2 Ep4 receptor agonist, compositions and methods thereof |
| 09/08/2004 | EP1453502A2 Pharmaceutical formulations comprising indolinone derivatives |
| 09/08/2004 | EP1453501A1 N- aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity |
| 09/08/2004 | EP1453500A1 Styryl acrylonitrile compounds and their use to promote myelopoiesis |
| 09/08/2004 | EP1453499A1 Use of 2-hydroxy or 2-acetyloxy-4-trifluoro-methylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment |
| 09/08/2004 | EP1453498A1 Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production |
| 09/08/2004 | EP1453497A1 Use for the treatment of gastroesophageal reflux disease |
| 09/08/2004 | EP1453496A2 Composition and method for modulating bar/fxr receptor activity |
| 09/08/2004 | EP1453495A2 Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists |
| 09/08/2004 | EP1453494A2 Sphingosine derivative as an immunoregulator compound |
| 09/08/2004 | EP1453493A2 Reversible proton pump inhibitors for the treatment of airway disorders |
| 09/08/2004 | EP1453492A2 Use of quinazolines to treat t-cell mediated diseases |
| 09/08/2004 | EP1453491A1 Transdermal delivery devices |
| 09/08/2004 | EP1453489A2 Acetaminophen compositions |
| 09/08/2004 | EP1453487A1 Pharmaceutical dosage form with multiple coatings |
| 09/08/2004 | EP1453483A2 High-concentration lidocaine compositions and methods for their preparation |
| 09/08/2004 | EP1453481A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 09/08/2004 | EP1453468A2 Method of vaccinating a human patient to prevent metastatic tumors |
| 09/08/2004 | EP1453467A2 Methods and compositions for modulating apoptosis |
| 09/08/2004 | EP1453447A1 Composition and transdermal drug delivery device |
| 09/08/2004 | EP1397503A4 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 09/08/2004 | EP1383512B1 Use of sucralfate for the treatment of cervical erosion |
| 09/08/2004 | EP1379261A4 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| 09/08/2004 | EP1347744B1 Solid dispersions of nitrate active principles |
| 09/08/2004 | EP1345603A4 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 09/08/2004 | EP1324761A4 Uridine therapy for patients with elevated purine levels |
| 09/08/2004 | EP1292313B1 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
| 09/08/2004 | EP1292281B1 Novel tiotropium-containing inhalation powder |
| 09/08/2004 | EP1289972B1 Serine protease inhibitors |
| 09/08/2004 | EP1289950B1 Serine protease inhibitors |
| 09/08/2004 | EP1267853B1 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 09/08/2004 | EP1254209A4 Bioavailable composition of natural and synthetic hca |
| 09/08/2004 | EP1235850B1 Unsaturated 14,15-cyclopropane-androstanes, a method for their production and pharmaceutical compositions containing these compounds |
| 09/08/2004 | EP1235571B1 Use of melatonin for treating androgenetic and diffuse female type alopecia |
| 09/08/2004 | EP1225897B1 Composition for treatment of constipation and irritable bowel syndrome |
| 09/08/2004 | EP1194416B1 Halopyrimidines |
| 09/08/2004 | EP1191932B1 Production of agglomerates of inogatran and the compound inogatran anhydrate |